LIVTENCITY

At a glance

Key dates

1. Approval

   FDA approval date of this drug product.

   Nov 23, 2021

   4 yr 8 mo ago

2. Today

3. Exclusivity ends · NCE

   New chemical entity exclusivity (5 years)

   Nov 23, 2026

   in 5 mo

4. Exclusivity ends · ODE-388

   Orphan-drug exclusivity (7 years)

   Nov 23, 2028

   in 2 yr 6 mo

5. Patent 12447169 expires

   Listed method-of-use patent (U-4329) expiration.

   Oct 27, 2031

   in 5 yr 5 mo

6. Patent 11684632 expires

   Listed method-of-use patent (U-3650) expiration.

   Jan 04, 2032

   in 5 yr 8 mo

7. Patent 12213989 expires

   Listed method-of-use patent (U-4137) expiration.

   Nov 18, 2042

   in 16 yr 8 mo

8. Patent 12433907 expires

   Listed method-of-use patent (U-4289) expiration.

   Nov 18, 2042

   in 16 yr 8 mo

9. Patent 12447170 expires

   Listed method-of-use patent (U-4328) expiration.

   Nov 18, 2042

   in 16 yr 8 mo

10. Patent 12295940 expires

    Listed drug substance patent expiration.

    Oct 11, 2043

    in 17 yr 7 mo

11. Patent 12527771 expires

    Listed drug substance patent expiration.

    Oct 11, 2043

    in 17 yr 7 mo

Pharmaceutical detail

This is a reference-listed drug (RLD) — the basis for generic (ANDA) applications. Other products sharing this ingredient are listed below.

Marketing exclusivity (2)

• NCENew chemical entity exclusivity (5 years)

  Nov 23, 2026

  in 5 mo

• ODE-388Orphan-drug exclusivity (7 years)

  Nov 23, 2028

  in 2 yr 6 mo

Listed patents (7)